Abstract
Antipsychotic drugs form a large group of psychoactive agents mainly known for their antipsychotic clinical properties, though they are also effective in a variety of nonpsychotic disorders. Originally, these drugs were named neuroleptics, because of their ability to mimic neurological syndromes,1 and this appellation is still in wide use, especially in the United States.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hyman SF, Arana GW,Rosenbaum JF: Handbook of Psychiatric Drug Therapy. Boston, Little, Brown and Company, pp. 5–42, 1995.
Davis J, Barter J, Kane J: Antipsychotic drugs, in Kaplan H, Sadock B (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams and Wilkins, pp 1591–1621, 1989.
Fish B, Shapiro T, Campbell M: Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry 123:32–39, 1966.
McClellan J, Werry J: The psychiatric clinics of North America, in Shaffer D (ed): Schizophrenia. Philadelphia, WB Saunders, 1996, pp 131–148.
Anderson L, Campbell M, Adams P, et al: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227–239, 1989.
Campbell M, Small A, Green W, et al: Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650–656, 1984.
Siefen G, Remschmidt H: Behandlungsergebnisse mit Clozapin bei schizophrenen Jugendlichen. Z Kinder-Jugendpsychiatr 14:245–257, 1986.
Muller-Spahn F: The International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: An international double-blind parallel-group study versus haloperidol. Clin Neuro-pharmacol 15:90A-91A, 1996.
Chouinard G, Jones B, Remington G, et al: A Canadian multicenter, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40, 1993.
Marder S: Risperidone: Clinical development: North American results. Clin Neuropharmacol 15:92A-93B, 1992.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC. American Psychiatric Association, 1994.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, DC. American Psychiatric Association Press, 1980.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, DC. American Psychiatric Association, 1987.
International classification of diseases ICD-9, in: Manual of the International Classification of Diseases, Injuries and Causes of Death. Geneva, World Health Organization, 1977.
Thompson J, Green D, Savit H: Preliminary report on a crosswalk from DSM-III to ICD-9-CM. Am J Psychiatry 140:176–180, 1983.
Physicians’ Desk Reference. Oradell, NJ. Medical Economics, 1992.
Simpson G. Pharmacology and treatment of the major psychoses. Paper presented at the 30th Annual Meeting of the American College of Neuropsychopharmacology, 1991.
Abnormal Involuntary Movements Scale. Psychopharmacol Bull 21:1077–1080, 1985.
Campbell M: Protocol for rating drug-related AIMS, stereotypies and CPRS assessments. Psychopharmacol Bull 21:1081, 1985.
Campbell M, Palij M: Measurement of untoward effects including tardive dyskinesia. Psychopharmacol Bull 21:1063–1082, 1985.
Campbell M, Spencer E, Kowalik S, et al: Schizophrenic and psychotic disorders, in Wiener J (ed): Textbook of Child and Adolescent Psychiatry. Washington, DC. American Psychiatric Association Press, pp 223–239,1991.
Spencer E, Kafantaris V, Padron-Gayol M, et al. Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull 28:183–186, 1992.
Spencer E, Alpert M, Pouget E: Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS. Psychopharmacol Bull 2:199–202, 1994.
Pool D, Bloom W, Mielke D, Roniger J, Gallant D: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res 19:99–104, 1976.
Realmuto G, Erickson W, Yellin A, et al: Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 141:440–442, 1984.
Kumra S, Jacobson L, Rapoport J: Childhood-onset schizophrenia: A double-blind clozapine trial. Paper presented at the 149th Annual Meeting of the American Psychiatric Association, 1996.
Gordon C, Frazier J, McKenna K, et al: Childhood-onset schizophrenia: An NIMH study in progress. Schizophr Bull 20:697–712, 1994.
Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R: Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 31:160–164, 1992.
Frazier J, Gordon C, McKenna K, Lenane M, Jih D, Rapoport J: An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:658–663, 1994.
Remschmidt H, Schulz E, Martin M, Warnke A, Trott G: Childhood-onset schizophrenia: History of the concept and recent studies. Schizophr Bull 20:727–745, 1994.
Blanz B, Schimdt M: Clozapine for schizophrenia. J Am Acad Child Adolesc Psychiatry 32:223–224,1993.
Remschmidt H, Schulz E, Martin P: An open trial of thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4:31–41, 1994.
Marder S, Meibach R: Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835,1994.
Armenteros J, Whitaker A, Joachim N, Jaffer M, Gorman J: An open trial of risperidone in adolescents with schizophrenia. Paper presented at the workshop on: Critical Issues in the Treatment of Schizophrenia. Campaign on Schizophrenia 1995, pp 176–177.
Cosgrove F: Recent advances in pediatric psychopharmacology [letter]. Hum Psychopharmacol 9:381–382, 1994.
Cozza S, Edison D: Risperidone in adolescents [letter]. J Am Acad Child Adolesc Psychiatry 33:1211, 1994.
Greevich S, Findling R. Schulz S, Rowane W: Risperidone in the treatment of children and adolescents with psychotic illness: A retrospective review. Paper presented at the 148th Annual Meeting of the American Psychiatric Association, 1995.
Simeon J, Carrey N, Wiggins D, Milin R, Hosenbocus S: Risperidone effects in treatment-resistant adolescents: Preliminary case reports. J Child Adolesc Psychopharmacol 5:69–79, 1995.
Sternlicht H, Wells S: Risperidone in childhood schizophrenia [letter]. J Am Acad Child Adolesc Psychiatry 34:540, 1995.
Werry J, McClellan J, Chard L: Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorder: A clinical and outcome study. J Am Acad Child Adolesc Psychiatry 30:457–465, 1991.
Geller B, Cooper T, Farooki Z, et al: Dose and plasma levels of nortriptyline and chlorpromazine in delusionally depressed adolescents and of nortriptyline in nondelusionally depressed adolescents. Am J Psychiatry 142:336–338, 1985.
Loranger A, Levine P: Age at onset of bipolar affective illness. Arch Gen Psychiatry 30:457–465, 1991.
Carlson G: Child and adolescent mania: Diagnostic considerations. J Child Psychol Psychiatry 31:331–341, 1990.
Shopsin B, Gershon S, Thompson H, et al: Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 32:34–42, 1975.
Calabrese J, Kimmel S, Woyshville M, et al: Clozapine for treatment-refractory mania. Am J Psychiatry 153:759–764, 1996.
Fuchs D: Clozapine treatment of bipolar disorder in a young adolescent. J Am Acad Child Adolesc Psychiatry 33:1299–1302, 1994.
Kowatch R, Suppes T, Gilfillan S, Fuentes R, Grannemann B, Emslie G: Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. J Am Acad Child Adolesc Psychopharmacol 5:241–253, 1995.
Campbell M, Gonzalez N, Silva R: Shaffer D (eds): The Pharmacologic Treatment of Conduct Disorders and Rage Outbursts. Philadelphia, WB Saunders, 1992, pp 69–85.
Cunningham M, Pillai V, Rogers W: Haloperidol in the treatment of children with severe behavioural disorders. Br J Psychiatry 114:845–854, 1968.
Werry J, Aman M, Lampen E: Haloperidol and methylphenidate in hyperactive children. Acta Paedo-psychiatr 42:26–40, 1975.
Greenhill L, Barmack J, Spalten D, et al: Molindone hydrochloride in the treatment of aggressive hospitalized children. Psychopharmacol Bull 17:125–127, 1981.
Greenhill L, Solomon M, Pleak R, et al: Molindone treatment of hospitalized children with conduct disorder. J Clin Psychiatry 46:20–25, 1985.
Children’s Psychiatric Rating Scale (CPRS). Psychopharmacol Bull 21:765–770, 1985.
Wong G, Cock R: Long-term effects of haloperidol on severely emotionally disturbed children. Aust NZ J Psychiatry 5:296–300, 1971.
Werry J, Aman M: Methylphenidate and haloperidol in children: Effects on attention, memory and activity. Arch Gen Psychiatry 32:790–795, 1975.
Piatt J, Campbell M, Green W, et al: Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Arch Gen Psychiatry 41:657–662, 1984.
Fras I, Major L: Clinical experience with risperidone [letter]. J Am Acad Child Adolesc Psychiatry 34:833, 1995.
Campbell M, Anderson L, Meier M, et al: A comparison of haloperidol, behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640–655, 1978.
Anderson L, Campbell M, Grega D, et al: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202, 1984.
Naruse H, Nagahata M, Nakane Y, et al: A multicenter double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 48:173–184, 1982.
Cohen I, Campbell M, Posner D, et al. Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry 19:665–677,1980.
Deutsch S, Campbell M: Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism. Neuropsychobiology 15:160–164, 1986.
Ernst M, Magee H, Gonzalez N, et al: Pimozide in autistic children. Psychopharmacol Bull 27:401–409,1992.
Campbell M: Pharmacotherapy in early infantile autism. Biol Psychiatry 10:399–423, 1975.
Campbell M, Schopler E: Pervasive developmental disorders, in Karasu TB (chairperson) (ed): Treatments of Psychiatric Disorders: A Task Force Report. Washington, DC, American Psychiatric Association Press, 1989, pp 179–294.
Tarjan C, Lowery V, Wright S: Use of chlorpromazine in two hundred seventy-eight mentally deficient patients. AMA J Disturbed Child 94:294–300, 1957.
Pregelj S, Barkauskas A: Thioridazine in the treatment of mentally retarded children. A four-year retroactive evaluation. J Can Psychiatr Assoc 12:213–215, 1967.
Freeman R: Psychopharmacology and the retarded child, in Menolascino F (ed): Psychiatric Approaches to Mental Retardation. New York, Basic Books, 1970, pp 294–368.
Campbell M, Fish B, Shapiro T, et al: Thiothixene in young disturbed children: A pilot study. Arch Gen Psychiatry 23:70–72, 1970.
Campbell M, Fish B, Shapiro T, et al. Study of molindone in disturbed preschool children. Curr Ther Res 13:28–33, 1971.
Locascio J, Malone R, Small A, et al: Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 27:119–126, 1991.
Rett A: Uber ein eingenartiges himtrophicshes Syndrome bei Hyperammonamie in Kindersalter. Wien Med Wochenschr 166:723–738, 1996.
Perry R, Campbell M, Adams P: Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28:87–92, 1989.
Die Trill M, Wolsky B, Shell J, et al: Effects of long term haloperidol treatment on intellectual functioning in autistic children: A pilot study. Paper presented at the 31st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 1984.
Shell J, Perry R, Adams P, et al: Effects of long-term haloperidol treatment on intellectual functioning in autistic children. Paper presented at the 34th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 1987.
McDougle C, Brodkin E, Yeung P, Naylor S, Cohen D, Price L: Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5:273–282, 1995.
Purdon S, Lit W, Labelle A, Jones B: Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400–405, 1994.
Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR: Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 7(3): 167–179, 1997.
Borison R, Ang L, Chang S, et al: New pharmacological approaches in the treatment of Tourette’s syndrome, in Friedhoff A, Chase T (eds): Gilles de la Tourette Syndrome. New York, Raven Press, 1982, pp 377–382.
Shapiro E, Shapiro A, Fulop G, et al: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 46:722–730, 1989.
Bruun R: Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am J Psychiatry 145:621–624, 1988.
Sallee FR, Nesbitt L, Jackson C, et al: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorders. Am J Psychiatry 154:1057–1062, 1997.
van der Linden C, Bruggeman R, van Woerkom T: Serotonin-dopamine antagonist and Gilles de la Tourette’s syndrome: An open pilot dose-titration study with risperidone. Mov Disord 9:687–688, 1994.
Lombroso P, Scahill L, King R, et al: Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. J Am Acad Child Adolesc Psychiatry 34:1147–1152, 1995.
Campbell M, Malone R: Mental retardation and psychiatry disorders. Hosp Community Psychiatry 42:374–379, 1991.
Aman M, Singh N: Psychopharmacology of the Developmental Disabilities. Berlin, Springer-Verlag, 1988, pp 1–28.
Aman M, Singh N: Pharmacotherapy and mental retardation, in Matson J, Mulick J (eds): Handbook of Mental Retardation. New York, Pergamon Press, 1991, pp 347–372.
Vanden Borre R, Vermote R, Buttiens M, et al: Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167–171, 1995.
Intagliata J, Rimck C: Psychoactive drug use in public and community residential facilities for mentally retarded persons. Psychopharmacol Bull 21:268–278, 1985.
Aman M: Drugs and learning in mentally retarded persons, in Burrows G, Werry J (eds): Advances in Human Psychopharmacology. Greenwich, Conn, JAI Press; 1984, pp 121–163.
Aman M, White A, Field C: Chlorpromazine effects on stereotypic and conditioned behaviour of severely retarded patients—a pilot study. J Ment Defic Res 28:253–260, 1984.
Claghorn J: A double-blind comparison of haloperidol (Haldol) and thioridazine (Mellaril) in outpatient children. Curr Ther Res 14:785–789, 1972.
Aman M, Singh N: Manual for the Abberant Behavior Checklist. East Aurora, NY, Slosson Educational Publications; 1986.
Aman M, Teehan C, White A, et al: Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. Am J Ment Retard 95:452–460, 1989.
Singh N, Aman M: Effects of thioridazine dosage on the behavior of severely mentally retarded persons. Am J Ment Defic 85:580–587, 1981.
Aman M, Marks R, Turbott S, et al: Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30:246–256, 1991.
White A, Aman M: Pimozide treatment in disruptive severely retarded patients. Aust N Z J Psychiatry 19: 92–94, 1985.
Goldberg J, Kurland A: Pimozide in the treatment of behavioral disorders of hospitalized adolescents. J Clin Pharmacol 14:134–139, 1974.
Aman M, Marks R, Turbott S, et al: Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 30: 816–824, 1991.
Gittelman-Klein R, Klein D, Katz S, et al: Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. Arch Gen Psychiatry 33:1217–1231, 1976.
Sleator E, von Neumann A, Sprague R: Hyperactive children: A continuous long-term placebo-controlled follow-up. JAMA 229:316–317, 1974.
Werry J, Weiss G, Douglas V, et al: Studies on the hyperactive child: III. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry 5:292–312, 1966.
Rapoport J, Abramson A, Alexander D, et al: Playroom observations on hyperactive children on medication. J Am Acad Child Psychiatry 10:524–534, 1971.
Aman M: Drugs, learning and the psychotherapies, in Werry J (ed): Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, Brunner/Mazel, 1978.
Davis K, Kahn R, Ko G, et al: Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474–1486, 1991.
Sokoloff P, Giros B, Martres M, et al: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–159, 1990.
Gould R, Murphy K, Reynolds I, et al: Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci USA 80:5122–5125, 1983.
Peroutka S, Snyder S: Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522, 1980.
Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45:331–336, 1984.
Farde L, Wiesel F, Stone-Elander S, et al: D2 receptors in neuroleptic naive schizophrenic patients. Arch Gen Psychiatry 47:213–219, 1990.
Pilowsky L, Costa D, Ell P, et al: Clozapine, single photon emission tomography and D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340:119–202, 1992.
Farde L, Nordstrom AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D 1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544, 1992.
Van Tol H, Bunzow J, Guan H, et al: Cloning of the gene for human D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–619, 1991.
Altar C, Wasley A, Neale R, et al: Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16:517–525, 1988.
Canton H, Verriele L, Colpaert F: Binding of typical and atypical antipsychotics to 5HT1C and 5HT2 sites. Eur J Pharmacol 191:93–96, 1990.
Robertson G, Fibiger H: Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46:315–328, 1992.
Meltzer H: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64–75, 1995.
Mandoki M: Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects. J Child Adolesc Psychopharmacol 5:49–67, 1995.
Baldessarini R, Teicher M: Dosing of antipsychotic agents in pediatric populations [editorial]. J Child Adolesc Psychopharmacol 5:1–4, 1995.
Synder S, Greenberg D, Yamamura H: Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31:58–61, 1974.
Ekblom B, Ericksson K, Lindstrom L: Super sensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacol Bull 83:293–294, 1984.
Dilsaver S, Greyden J: Antidepressant withdrawal phenomena. Biol Psychiatry 19:237–256, 1984.
Dilsaver S, Feinberg M, Greyden J: Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 140:249–251, 1983.
Chouinard G: Severe cases of neuroleptic-induced super sensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5:21–33, 1990.
Geller B: Psychopharmacology of children and adolescents: Pharmacokinetics and relationships of plasma/ serum levels to response. Psychopharmacol Bull 27:401–409, 1991.
Furlanut M, Benetello P, Baraldo M, et al: Chlorpromazine disposition in relation to age in children. Clin Pharmacokinet 18:329–331, 1990.
Morselli P, Bianchetti G, Durand G, et al: Haloperidol plasma level monitoring in pediatric patients. Ther Drug Monit 1:35–46, 1979.
Poland R, Campbell M, Rubin R, et al: Relationship of serum haloperidol levels and clinical response in autistic children. Paper presented at the 13th CINP Congress (Collegium Internationale Psychophar-macologicum), Jerusalem, 1982.
Rivera-Camlimlin L, Griesbach P, Perlmutter R: Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness. Clin Pharmacol Ther 26:114–121, 1979.
Campbell M, Poland R, Perry R, et al: Serum haloperidol levels and prolactin levels and clinical response in autistic children. Paper presented at the 35th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Seattle, 1988.
Brosen K: Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239, 1990.
Rivera-Camlimlin L, Nasrallah H, Strauss J, et al. Clinical response and plasma levels: Effect of dose, dosage, schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133:652, 1976.
Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 41:369–371, 1991.
Goff DC, Baldessarini RJ: Antipsychotics, in Ciraulo DA, Shader RA, Greenblatt DJ, Creelman W (eds): Drug Interactions in Psychiatry. Baltimore, Williams & Wilkins, 1995, pp 129–174.
Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli, Flood JG: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820–822, 1996.
Ciraulo DA, Shader RI: Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 10:48–50, 1990.
Mikkelson E, Detlor J, Cohen D: School avoidance and social phobia trigerred by haloperidol in patients with Tourette’s disorder. Am J Psychiatry 138:1572–1575, 1981.
Baldasserini R: Drugs and the treatment of psychiatric disorders, in Gilman A, Rall T, Nies A (eds): Goodman and Gilmans The Pharmacological Basis of Therapeutics. New York, Maxwell/McMillan; 1991, pp 383–437.
Schmidt MH, Trott GE, Blanz B, Nissen G: Clozapine medication in adolescents, in Psychiatry: A World Perspective, Stefania CN, Rabavilas AD, Soldates CR (eds). Amsterdam: Excerpta Medica, Proceedings of the VIII World Congress of Psychiatry, 1990, vol 1, pp 1100–1104.
Keepers G, Clappison V, Casey D: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117, 1983.
Richardson M, Haughland G, Craig T: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 148:1322–1328, 1991.
Kane J, Jeste D, Barnes T, et al: Tardive Dyskinesia: A Task Force Report. Washington, DC, American Psychiatric Association Press; 1991.
Delay J, Deniker P: Drug-induced extrapyramidal syndromes, in Vinken P, Bruyn G (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland Publishing Co, 1968, pp 248–266.
Rifkin A, Quitkin F, Klein D: Akinesia: A poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32:672–674, 1975.
Van Putten T, Mutalipassi L, Malkin M: Phenothiazine-induced decompensation. Arch Gen Psychiatry 30:102–105, 1974.
Van Putten T, May P, Marder S: Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036–1039, 1984.
Campbell M, Adams P, Perry R, et al: Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacol Bull 24:251–255, 1988.
Campbell M, Grega D, Green W, et al: Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol 6:207–222, 1983.
Perry R, Nobler M, Campbell M: Case report: Tourette-like symptoms associated with chronic neuroleptic therapy in an autistic child. J Am Acad Child Adolesc Psychiatry 28:93–96, 1989.
Klawans H, Nausieda P, Goetz C, et al: Tourette-like symptoms following chronic neuroleptic therapy, in Friedhoff A, Chase T (eds): Advances in Neurology. New York, Raven Press, 1982.
Smith R, Domino E: Dystonic and dyskinetic reactions induced by H1 antihistaminc medication, in Fann W, Smith R, Davis J, et al (eds): Tardive Dyskinesia: Research and Treatment. Jamaica, NY, Spectrum Publications; 1980, pp 325–332.
Thach B, Chase T, Bosnian J: Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Med 293:486–487, 1975.
Chadwick D, Reynolds E, Marsden C: Anticonvulsant induced dyskinesias. J Neurol Neurosurg Psychiatry 39:1210–1218, 1979.
Gardos G, Cole J, La Brie R: The assessment of tardive dyskinesia. Arch Gen Psychiatry 34:1206–1212, 1977.
Gerlach J: Pathophysiological mechanisms underlying tardive dyskinesia, in Casey D, Chase T, Christensen D, et al (eds): Dyskinesia—Research and Treatment (Psychopharmacology Suppl 2). Berlin, Springer-Verlag, 1985, pp 99–103.
Kane J, Smith J: Tardive dyskinesia. Arch Gen Psychiatry 39:473–481, 1982.
Crane G, Naranjo E: Motor disorders induced by neuroleptics. Arch Gen Psychiatry 24:178–184, 1971.
Gardos G, Cole J, Tarsy D: Withdrawal symptoms associated with antipsychotic drugs. Am J Psychiatry 135:1321–1324, 1978.
McAndrew J, Case Q, Treffert D: Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J Autism Child Schizophr 2:75–91, 1972.
Gualtieri C, Quade D, Hicks R, et al: Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 141:20–23, 1984.
Engelhardt D, Polizios P: Adverse effects of pharmacotherapy in childhood psychosis, in Lipton M, DiMascio A, Killam K (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press; 1978.
Owens D, Johnstone E, Frith C: Spontaneous involuntary disorders of movement: Their prevalence, severity and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 39:452–461, 1982.
Meiselas K, Spencer E, Oberfield R, et al: Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children. J Clin Psychopharmacol 9:207–209, 1989.
Schooler, N, Kane J: Research diagnoses for tardive dyskinesia [letter to the editor]. Arch Gen Psychiatry 39:486–487, 1982.
Campbell M, Locascio J, Choroco M, et al: Stereotypies and tardive dyskinesia: Abnormal movements in autistic children. Psychopharmacol Bull 26:260–266, 1990.
Malone R, Ernst M, Godfrey K, Locascio J, Campbell M: Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol Bull 27:113–117, 1991.
Kane J, Honigfeld G, Singer J, Meltzer H: Clozaril Collaborative Study Group: Clozapine for the treatment-treatment resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796, 1988.
Woener M, Sheitman B, Lieberman J, Kane J: Tardive dyskinesia induced by risperidone? [letter]. Am J Psychiatry 153:843, 1996.
Crane G: Neuroleptics and their long-term effects on the central nervous system, in DeVeaugh-Geiss J (ed): Tardive Dyskinesia and Related Involuntary Movement Disorders. Boston, John Wright Publishing Co, 1982, pp 71–84.
McLean P, Casey D: Tardive dyskinesia in an adolescent. Am J Psychiatry 135:969–971, 1978.
Villeneuve A: The rabbit syndrome: A peculiar extrapyramidal reaction. Can J Psychiatry 17:69–72, 1972.
Campbell M, Cohen I, Small A: Drugs in aggressive behavior. J Am Acad Child Psychiatry 21:107–117, 1982.
Spencer EK, Campbell M: Children with schizophrenia: Diagnosis, phenomenology and pharmacotherapy. Schizophr Bull 20(4):713–725, 1994.
Simpson G: APA Task Force on Sudden Death. Washington, DC, American Psychiatric Association Press, 1987.
Silver J, Yudofsky S: Psychopharmacology and electroconvulsive therapy, in Talbott J, Hales R, Yudofsky S (eds): The American Psychiatric Press Textbook of Psychiatry. Washington, DC, American Psychiatric Press; 1989, pp 767–843.
Levinson F, Simpson G: Neuroleptic-induced extrapyramidal symptoms with fever. Arch Gen Psychiatry 43:839–848, 1986.
Geller B, Greydanus D: Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: Two case reports with a literature review. J Clin Psychiatry 40:102–103, 1979.
Klein S, Levinsohn M, Blumer J: Accidental chlorpromazine ingestion as a cause of neuroleptic malignant syndrome in children. J Pediatr 107:970–973, 1985.
Green WH, Campbell M, Wolsky BB: Effects of short and long term haloperidol administration on growth in young autistic children. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, 1984.
Hamill PVV, Drizd TA, Johnson CL, et al: NCHS Growth Charts, 1976. Monthly Vital Statistics Report, Health Examination Survey Data, National Center for Health Statistics Publication (HRA) 76–1120, 25(3): 1–22, 1976.
Van Kammen D, Marder S: Biological therapies: Clozapine, in Kaplan H, Sadock B (eds): Comprehensive Textbook of Psychiatry VI. Baltimore, Williams & Wilkins, 1995.
Rapoport J: Clozapine and child psychiatry [editorial]. J Child Adolesc Psychopharmacol 4:1–3, 1994.
Lieberman J, Yunis J, Egea E, Conoso R, Kane J, et al: HLA B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 47:945–948, 1990.
Haller E, Binder R: Clozapine and seizures. Am J Psychiatry 147:1069–1071, 1990.
Freedman J, Wirshing W, Russell A, Palmer Bray M, Unutzer J: Absence status seizures during successful long-term treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol 4:53–62, 1994.
Birmaher B: Clozapine for child and adolescent schizophrenia. Child Adolesc Psychopharmacol News 1: 1–4, 1996.
Simpson G, Lee J, Shrivastava R: Clozapine in tardive dyskinesia. Psychopharmacology 56:75–80, 1978.
Alphs L, Lee H: Comparison of withdrawal or dose reduction of clozapine. J Clin Psychiatry 52:346–348, 1991.
Eklund K: Super sensitivity and clozapine withdrawal. Psychopharmacology 91:135, 1987.
Borison R, Diamond B, Sinha D, Gupta R, Prince Ajiboye A: Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260–263, 1988.
Allen MD, Greenblatt DJ, Noel BJ: Overdose with antipsychotic agents. Am J Psychiatry 137:234–236, 1980.
Cunningham DG, Challapalli M: Hypertension in acute haloperidol poisoning. J Pediatr 95:489–490, 1979.
Giannini AJ: Psychotropic Drug Overdose. New York, Hemisphere Publishing Corp., 1992, p 39.
Buckley NA, Whyte IM, Dawson AH: Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Clin Toxicol 33:199–204, 1995.
Krishel S, Jackimczyck K: Antidepressants, lithium, and neuroleptic agents. Psychiatr Asp Emerg Med 9:53–85, 1991.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ernst, M., Malone, R.P., Rowan, A.B., George, R., Gonzalez, N.M., Silva, R.R. (1999). Antipsychotics (Neuroleptics). In: Werry, J.S., Aman, M.G. (eds) Practitioner’s Guide to Psychoactive Drugs for Children and Adolescents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0086-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0086-9_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-45885-9
Online ISBN: 978-1-4899-0086-9
eBook Packages: Springer Book Archive